Globo-H Antigen Vaccine Development Service
Your Reliable Partner for Globo-H Antigen Vaccine Development
Globo-H (GH), Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glc, is a ceramide-linked glycolipid. It is expressed as a glycolipid or glycoprotein on the surface of cancer cells. Carbohydrate Click-based Sugar-conjugated Vaccine Development requires the recognition of unique markers and preferably is expressed only on cancer cells. GH is widely expressed in prostate cancer cells and is an effective target for anticancer vaccine development. Based on this property, CD BioGlyco provides a high-quality GH antigen vaccine development service that includes the design and synthesis of GH antigens, modification, and immune assessment. Our synthetic team has great experience in the design and development of GlycoCLICK™-based Vaccine Development. Moreover, we provide Triazole Skeleton-based Vaccine and Multivalent Glycopeptide-lipopeptide Vaccine development services.
- Vaccine Preparation
CD BioGlyco provides customized synthesis services based on client needs by a professional synthesis team. We synthesize GH by click reaction through glycosyl assembly. We convert the allyl group at the end of the fully synthesized constructs to the aldehyde group by ozonolysis and attach it to the amino group on the bifunctional crosslinker. Furthermore, with the help of click chemistry, the building blocks are assembled.
GH antigen alone has low immunogenicity and is difficult to induce IgG antibodies and T-cell-dependent responses. Therefore, we offer GH antigen modification services such as azide modification. Our researchers use galactose oxidase to selectively oxidize at their terminal Gal or GalNAc to 6-aldehyde, which are converted to 6-azide derivatives by chemical transformation.
- Immune Assessment
CD BioGlyco provides customized dose and immunization schedules according to different project characteristics. We provide mouse animal model construction services. Our researchers immunize the mice on time and observe their status (e.g., body weight, inflammation, death) at all times. In addition, we provide services to study the mechanism of uptake, processing, and delivery of GH vaccines in the immune system. We provide the following services:
- Serologic assay
- Complement-mediated cytotoxicity assay
- Enzyme-linked immunosorbent assay (ELISA)
- Flow cytometric analysis
- Analysis of in vivo distribution
- Biostatistical assessment
Fig.1 Schematic diagram of GH antigen vaccine development service. (CD BioGlyco)
Publication
Technology: ELISA, Glycan array, Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Journal: Journal of the American Chemical Society
IF: 16.383
Published: 2023
Results: In this study, we synthesized an oligosaccharide-conjugated cancer vaccine prepared from the glycans of the globular series Globo-H. Upon analysis, this vaccine was shown to induce antibodies against the glycan portion of all three ball-series GSLs. The mechanisms of antigen processing and delivery of the oligosaccharide fraction of the GH-diphtheria toxin (DT) vaccine were investigated by animal models. This work facilitates the design and development of glycoconjugate vaccines based on carbohydrate-click antigens.
Fig.2 Specificity analysis factor design results. (Wang, et al., 2023)
Applications
- GH antigen vaccine development promotes the development of chemically combined immunology and cancer biology.
- GH antigen vaccine is effective as a cancer treatment tool.
- GH antigen vaccine plays a key role in treating treatment after prostatectomy or radiotherapy.
CD BioGlyco provides vaccine development services based on scientific research use, not as clinical treatments. Our superior service and serious attitude are recognized by clients around the world. Please feel free to contact us if you want to learn more about GH antigen vaccine development.
References
- Danishefsky, S.J.; et al. Development of Globo-H cancer vaccine. Accounts of chemical research. 2015, 48(3): 643-652.
- Wang, S.W.; et al. Mechanism of antigen presentation and specificity of antibody cross-reactivity elicited by an oligosaccharide-conjugate cancer vaccine. Journal of the American Chemical Society. 2023, 145(17): 9840-9849.
For research use only. Not intended for any clinical use.
Related Services
